NCT06920069View on ClinicalTrials.gov

Study of Concomitant Administration of the sIPV and DTaP or MMR

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

2,640

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

July 15, 2030

Study Completion Date

June 15, 2031

Conditions
PolioDiphteria, Tetanus and PertussisMMR Vaccine
Interventions
BIOLOGICAL

sIPV

Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose

BIOLOGICAL

DTaP

Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose

BIOLOGICAL

bOPV 1,3

Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose

BIOLOGICAL

MMR Vaccine

Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose

Trial Locations (9)

651299

Lufeng Center for Disease Control and Prevenion, Chuxiong

651300

Yuanmou Center for Disease Control and Prevention, Chuxiong

651600

Wuding Center for Disease Control and Prevention, Chuxiong

652399

Mile Center for Disease Control and Prevention, Yisa

663100

Yanshan Center for Disease Control and Prevention, Wenshan

663200

Qiubei Center for Disease Control and Prevention, Wenshan

663300

Guangnan Center for Disease Control and Prevention, Wenshan

665699

Lancang Center for Disease Control and Prevention, Puer

675300

Yaoan Center for Disease Control and Prevention, Chuxiong

All Listed Sponsors
lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER